Endometriosis Pipeline H2 2015 Market Research Report

PUNE, India, December 1, 2015 /PRNewswire/ --

ReportsnReports.com adds "Endometriosis - Pipeline Review, H2 2015" market research report that provides an overview on therapeutic pipeline of Endometriosis and helps enhance decision making capabilities to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on Endometriosis Pipeline Review spread across 131 pages, analyzing 22 companies and supported with 43 tables and 16 figures is now available at http://www.reportsnreports.com/reports/444207-endometriosis-pipeline-review-h2-2015.html .

This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects.

The report provides a snapshot of the global therapeutic landscape of Endometriosis. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects and a review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Order a copy of Endometriosis - Pipeline Review, H2 2015 market research report at http://www.reportsnreports.com/purchase.aspx?name=444207 .

Top Companies covered in this report AbbVie Inc., Addex Therapeutics Ltd, APAvadis Biotechnologies Srl, Astellas Pharma Inc., Bayer AG, Dongkook Pharmaceutical Co., Ltd., ElexoPharm GmbH, EndoCeutics, Inc., Enteris BioPharma, Inc., Euroscreen S.A., Evotec AG, Forendo Pharma Oy, GlaxoSmithKline Plc, Kissei Pharmaceutical Co., Ltd., Lipicard Technologies Limited, Nippon Shinyaku Co., Ltd., Orphagen Pharmaceuticals, Inc., Philogen S.p.A., Repros Therapeutics Inc., SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Limited and ValiRx Plc.

Drug Profiles discussed in this report are (anastrozole + levonorgestrel), acolbifene hydrochloride + prasterone + GnRH agonist, ADX-68692, ASP-1707, BAY-1128688, bentamapimod, Drug to Inhibit C-Jun for Endometriosis, Drugs for Endometriosis, Drugs for Endometriosis and Uterine Fibroids, elagolix sodium, epelsiban besylate, ESN-364, EVE-104, FP-5677, goserelin, KLH-2109, leuprolide acetate, LT-6121, Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis, NCE-403, NS-580, Peptides for Cancer and Endometriosis, Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis, PGL-2001, Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome, relugolix, Small Molecule to Antagonize FSH Receptor for Women's Health, Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology, Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis, Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease, Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis, Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers, Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis, SR-16234, Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology, telapristone acetate, Tetravil, triptorelin pamoate, VAL-201, vilaprisan, VPE-001 and VPEA-004.

Another newly published market research titled Pre-Eclampsia - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. This report spread across 59 pages is available at http://www.reportsnreports.com/reports/428021-pre-eclampsia-pipeline-review-h2-2015.html .

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:  http: //www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

SOURCE ReportsnReports